NCSS experts identified the key challenges of import substitution and quality control of new dosage forms

Experts from the National Center for Standard Samples took part in the IX Pharmaceutical Summit "Registration, Pharmacovigilance and Clinical Research: New Horizons and best practices", where they discussed the current challenges of the pharmaceutical industry in the context of import substitution, as well as modern approaches to quality control of new dosage forms.

The IX Pharmaceutical Summit, held on February 5-6 in Moscow at the Lomonosov cluster, brought together representatives of pharmaceutical companies, laboratories and the expert community to discuss key regulatory and technological trends in the industry.

As part of the business program, NCSS experts presented a practical view on issues that directly affect the sustainability and development of pharmaceutical production.

The main part of the speech by Vladimir Gegechkori, Director for Production and Certification of Reference materials at NCSS, was a discussion of the challenges the pharmaceutical industry is facing today in the context of import substitution.

In his report, he noted the role of the NCSS as one of the elements of the sustainability of the industry, and also spoke about the advantages of the Center and the range of laboratory services that allow pharmaceutical manufacturers to ensure quality, reproducibility and regulatory traceability at all stages of the life cycle of medicines.

Dmitry Chepilo, Head of the NCSS Testing laboratory, dedicated his presentation to the emergence of new dosage forms and modern methods of their control. The expert spoke about approaches to assessing the quality of innovative medicines and how exactly new dosage forms are monitored in the laboratory.

NCSS's participation in the summit has become an excellent platform for sharing practical experience and discussing current challenges facing the pharmaceutical industry in the current environment.